Skip to main content

Advertisement

ADVERTISEMENT

News

News
03/24/2020
Lenvatinib plus pembrolizumab has shown promise in patients with advanced endometrial cancer, regardless of tumor MSI status.
Lenvatinib plus pembrolizumab has shown promise in patients with advanced endometrial cancer, regardless of tumor MSI status.
Lenvatinib plus pembrolizumab...
03/24/2020
Oncology
News
09/17/2019
The FDA granted accelerated approval to the combination of pembrolizumab and lenvatinib for the treatment of advanced endometrial carcinoma that is not MSI-H or dMMR, and disease that progresses following prior systemic therapy.
The FDA granted accelerated approval to the combination of pembrolizumab and lenvatinib for the treatment of advanced endometrial carcinoma that is not MSI-H or dMMR, and disease that progresses following prior systemic therapy.
The FDA granted accelerated...
09/17/2019
Oncology
News
08/29/2019
Combining adjuvant chemo with radiotherapy significantly improved OS and RFS versus radiotherapy alone in women with high-risk endometrial cancer.
Combining adjuvant chemo with radiotherapy significantly improved OS and RFS versus radiotherapy alone in women with high-risk endometrial cancer.
Combining adjuvant chemo with...
08/29/2019
Oncology

Advertisement

News
05/06/2019
A recent study did not demonstrate the superiority of vaginal cuff brachytherapy plus chemotherapy over pelvic radiation therapy in patients with early-stage endometrial cancer.
A recent study did not demonstrate the superiority of vaginal cuff brachytherapy plus chemotherapy over pelvic radiation therapy in patients with early-stage endometrial cancer.
A recent study did not...
05/06/2019
Oncology
News
04/10/2019
Results from a phase 2 trial suggest that lenvatinib plus pembrolizumab is a novel combination therapy option for patients with advanced recurrent endometrial cancer.
Results from a phase 2 trial suggest that lenvatinib plus pembrolizumab is a novel combination therapy option for patients with advanced recurrent endometrial cancer.
Results from a phase 2 trial...
04/10/2019
Oncology
News
04/08/2019
Regimens combining taxane and platinum are feasible alternatives to doxorubicin plus cisplatin in adjuvant chemotherapy for patients with endometrial cancer.
Regimens combining taxane and platinum are feasible alternatives to doxorubicin plus cisplatin in adjuvant chemotherapy for patients with endometrial cancer.
Regimens combining taxane and...
04/08/2019
Oncology

Advertisement

News
03/01/2019
Implementation of minimally invasive robotic surgery for early stage endometrial cancer has been associated with a reduced risk for severe complications.
Implementation of minimally invasive robotic surgery for early stage endometrial cancer has been associated with a reduced risk for severe complications.
Implementation of minimally...
03/01/2019
Oncology
News
03/02/2018
Adjuvant chemotherapy given during and after pelvic radiation for high-risk endometrial cancer improves failure-free, but not overall, survival at five years and may be discussed as an alternative to radiation alone.
Adjuvant chemotherapy given during and after pelvic radiation for high-risk endometrial cancer improves failure-free, but not overall, survival at five years and may be discussed as an alternative to radiation alone.
Adjuvant chemotherapy given...
03/02/2018
Oncology

Advertisement